Table 1.
Pooled Estimates for the Association of Firefighting with Different Cancers
Cancer Site | Risk Estimate (95% CI) [number of studies] |
||
---|---|---|---|
Incidence |
Mortality |
Incidence and Mortality |
|
Cancer sites with statistically significant findings and generally consistent point estimates | |||
Brain and CNS | |||
Good Studies only | 0.87 (0.55 – 1.37) [4] | 1.31 (0.85 – 2.01) [9] | 1.19 (0.84 – 11.68) [11] |
Good and Adequate | 1.27 (0.89 – 1.80) [7] | 1.24 (0.86 – 1.77) [11] | 1.25 (0.99 – 1.59) [16] |
All Studies | 1.27 (0.89 – 1.80) [7] | 1.26 (1.02 – 1.55)* [18] | 1.26 (1.06 – 1.50)* [24] |
Non-Hodgkin’s Lymphoma | |||
Good Studies only | 1.11 (0.73 – 1.68) [3] | 1.25 (0.73 – 2.61) [2] | 1.20 (0.90 – 1.61) [5] |
Good and Adequate | 1.07 (0.91 – 1.24) [5] | 1.40 (0.99 – 1.96) [3] | 1.12 (0.97 – 1.28) [8] |
All Studies | 1.36 (0.85 – 2.18) [6] | 1.44 (1.27 – 1.63) ** [7] | 1.37 (1.14 – 1.64) ** [13] |
Skin Melanoma | |||
Good Studies only | 1.20 (0.86 – 1.68) [4] | 0.69 (0.22 – 2.18) [2] | 1.15 (0.83 – 1.59) [5] |
Good and Adequate | 1.10 (0.77 – 1.58) [6] | 1.40 (0.46 – 4.30) [3] | 1.22 (0.87 – 1.71) [8] |
All Studies | 1.10 (0.77 – 1.58) [6] | 1.62 (1.26 – 2.10) ** [6] | 1.34 (1.09 – 1.65)* [11] |
Colorectal | |||
Good Studies only | 1.04 (0.91 – 1.89) [13] | 1.21 (1.07 – 1.36)* [25] | 1.14 (1.03 – 1.25)* [14] |
Good and Adequate | 1.05 (0.93 – 1.19) [17] | 1.21 (1.08 – 1.35)* [27] | 1.13 (1.04 – 1.24)* [18] |
All Studies | 1.08 (0.95 – 1.22) [18] | 1.16 (1.07 – 1.25)** [42] | 1.13 (1.06 – 1.21)* [28] |
Colon | |||
Good Studies only | 1.10 (0.91 – 2.48) [4] | 1.14 (0.93 – 1.39) [9] | 1.11 (0.94 – 1.30) [10] |
Good and Adequate | 1.22 (1.05 – 1.42)* [6] | 1.14 (0.93 – 1.39) [9] | 1.18 (1.04 – 1.34)* [13] |
All Studies | 1.26 (1.10 – 1.44)**[7] | 1.10 (0.99 – 1.26) [16] | 1.15 (1.05 – 1.26)* [21] |
Rectal | |||
Good Studies only | 1.06 (0.80 – 1.42) [4] | 1.34 (1.05 – 1.72)* [8] | 1.22 (1.01 – 1.47)* [10] |
Good and Adequate | 0.99 (0.78 – 1.24) [5] | 1.34 (1.08 – 1.67)* [9] | 1.16 (0.99 – 1.36) [12] |
All Studies | 0.99 (0.78 – 1.24) [5] | 1.25 (1.09 – 1.44) ** [16] | 1.18 (1.04 – 1.34)* [19] |
Bladder | |||
Good Studies only | 1.18 (0.97 – 1.43) [6] | 1.39 (0.91 – 2.11) [9] | 1.24 (0.98 – 1.57) [14] |
Good and Adequate | 1.06 (0.88 – 1.27) [9] | 1.38 (0.98 – 1.95) [11] | 1.20 (0.98 – 1.45) [19] |
All Studies | 1.06 (0.88 – 1.27) [9] | 1.28 (1.05 – 1.56)* [17] | 1.18 (1.01 – 1.36)* [25] |
Prostate | |||
Good Studies only | 1.14 (0.90 – 1.45) [7] | 1.20 (0.76 – 1.90) [9] | 1.17 (0.90 – 1.53) [15] |
Good and Adequate | 1.15 (1.01 – 1.32)* [9] | 1.20 (0.76 – 1.90) [9] | 1.19 (0.98 – 1.44) [17] |
All Studies | 1.21 (1.04 – 1.42)* [11] | 1.27 (1.01 – 1.61)* [16] | 1.26 (1.10 – 1.45)** [26] |
Testicular | |||
Good Studies only | 1.58 (1.23 – 2.03) ** [3] | 2.52 (0.67 – 9.49) [1] | 1.61 (1.26 – 2.06) ** [4] |
Good and Adequate | 1.73 (1.31 – 2.27) ** [7] | 2.52 (0.67 – 9.49) [1] | 1.73 (1.35 – 2.23) ** [8] |
All Studies | 1.73 (1.31 – 2.27) ** [7] | 1.63 (0.60 – 4.40) [3] | 1.68 (1.35 – 2.08) ** [10] |
Risk estimates and confidence intervals in all tables were derived using STATA; * P < 0.05; ** P < 0.001